AimwellBio Launches Public AI Signal Feed, Challenging Biopharma Intelligence Industry to Verify Before Trusting
核心洞察
AimwellBio (搜索) has launched a public signal feed displaying 419 regulatory, clinical, and research signals with no login, sales call, or credentials required for inspection.
The feed spans four institutional source categories: 200 Phase II/III clinical trial signals, 69 FDA enforcement actions, 150 peer-reviewed research signals, and EMA safety alerts.
CEO John Morgan stated the public feed is "a standing invitation: come count," challenging the intelligence industry's practice of requiring trust before verification.
Aimwell Partners Inc. (搜索) (OTC: AIMN), the parent company of AimwellBio (搜索), has launched a publicly accessible signal feed that displays 419 regulatory, clinical, and research intelligence signals without requiring a login, sales conversation, or any form of credentialing. The feed, available at aimwellbio.com/signals, represents a deliberate departure from industry norms where AI intelligence platforms typically gate their data behind intake forms and non-disclosure agreements.
"The intelligence industry has trained buyers to accept claims that cannot be checked," said John Morgan, CEO of AimwellBio (搜索). "We think that era is ending, and we would rather end it ourselves than have it ended for us. The public feed is not a marketing asset. It is a standing invitation: come count."
What the Public Feed Contains
The public-tier feed currently displays 419 signals drawn from four institutional source categories. These include 200 Phase II and Phase III clinical trial signals tracked from ClinicalTrials.gov and NIH registries on a scheduled refresh cycle, 69 FDA enforcement actions and recall alerts monitored from public U.S. Food and Drug Administration reporting, 150 peer-reviewed research signals indexed and scored from PubMed and NCBI biomedical literature, and European Medicines Agency safety alerts, CHMP opinions, and regulatory decisions monitored on a scheduled refresh cycle.
Every figure displayed on the page can be independently counted by any visitor. That verifiability is the core proposition.
The Distinction Between Public Feed and Platform
AimwellBio (搜索) draws a clear line between its public signal feed and its full platform architecture. The public feed is described as the visible layer, while the company's complete system continuously indexes a substantially larger corpus of regulatory and scientific intelligence across 13 independent institutional source streams. Cross-validation is applied to every intelligence output before delivery to subscribers.
The company states plainly that the 419-signal public feed represents launch-tier directional metrics that evolve as the platform matures and are not audited performance claims. "A biopharma executive evaluating intelligence vendors should ask one question first," Morgan added. "Can I see the signal layer before I sign anything? If the answer is no, that tells you what you need to know. Our answer is a URL."
Why Transparency Matters Now
Organizations across biopharma are increasingly making regulatory, clinical, and capital decisions informed by AI-generated intelligence, while public enforcement activity continues to increase and regulators remain focused on health claim compliance and disclosure standards. The cost of acting on unverifiable intelligence, the company argues, can manifest as recalls, delayed filings, consent decrees, compliance failures, and board-level exposure.
AimwellBio (搜索)'s response is structural: source-traced outputs, adversarial validation, confidence labeling, and now a public evidence layer that allows professionals to inspect the signal stream before committing to any subscription.
Access and Availability
The public signal feed is available now at aimwellbio (搜索).com/signals. Observer-level platform access remains available at no cost to credentialed professionals. Individual subscriptions begin at $229 per month, with enterprise and institutional deployment inquiries accepted at aimwellbio.com/request-access. The company's Adversarial Validation Standard is publicly available at aimwellbio.com/standard.
AimwellBio (搜索) describes itself as a decision intelligence platform purpose-built for biopharmaceutical organizations, continuously monitoring regulatory, clinical, and competitive developments and synthesizing them into verified, hallucination-contained intelligence outputs for R&D leaders, regulatory affairs professionals, compliance teams, and life sciences investors.